Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05081999 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease

Study acronym: ABBREVIATE
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: estimated 8500 to confirmed 59
    • Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Dec 31, 2026 to Jan 31, 2026
    • Site details revised
    v8
  2. 2 versions Re-verified since Feb 1, 2024, no change to tracked fieldsv6-v7
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 1, 2023 to Jan 30, 2023
    • Site details revised
    v5
  4. Start date: Dec 1, 2022 to Feb 1, 2023v4
  5. Start date: Oct 1, 2022 to Dec 1, 2022v3
  6. Start date: Jun 1, 2022 to Oct 1, 2022v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with heart disease are often prescribed many medications and these patients may experience drug interactions or negative drug related side effects. With newer medications and treatments available, it is not well known whether older drugs, such as beta-blockers, are still an effective and safe option for treating heart disease. Some evidence suggests beta-blockers should be continued, whereas other evidence suggests beta-blockers might cause unnecessary harm. The study hopes to determine whether continuation or discontinuation of beta-blockers will affect long term cardiovascular outcomes. The study investigators will also examine how beta-blockers continuation or discontinuation affects several quality of life measures.
Trial Details
NCT Number NCT05081999
Lead Sponsor University of Alberta
Conditions
(from sponsor)		 Stable Ischemic Heart Disease, Coronary Artery Disease, Beta-blocker Therapy
Related terms Coronary Artery Disease
Enrollment 59 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov